placebo + remdesivir

placebo + remdesivir refers to the control arm of a Phase III clinical trial (NCT04645394) conducted by Daewoong Pharmaceutical Co. Ltd. to evaluate the efficacy and safety of DWJ1248 (camostat mesylate) in patients with severe COVID-19. In this arm, patients receive an oral placebo alongside intravenous remdesivir, which serves as the standard-of-care comparator. Remdesivir is a nucleotide analog prodrug that, once metabolized into its active triphosphate form, competes with adenosine triphosphate for incorporation into the viral RNA strand by the SARS-CoV-2 RNA-directed RNA polymerase (RdRp). This incorporation leads to delayed chain termination during viral RNA replication, effectively inhibiting the spread of the virus within the host. The placebo component is an inactive oral tablet designed to match the appearance and administration schedule of camostat mesylate.

Brand names

Veklury

Other names

Placebo with Remdesivir